Table 2.
|
|
Exacerbation |
|
|
---|---|---|---|---|
|
During exacerbation |
Follow-up |
Stable |
|
|
(n = 19) |
(n = 17) |
(n = 10) |
|
Day 1 | Day 14 | Day 40 | ||
Spirometry | ||||
FEV1 (L) |
2.1 ± 0.9**,# |
2.7 ± 1.1# |
2.4 ± 1.0 |
2.8 ± 1.0 |
FEV1 (%pred) |
55 ± 19**,## |
69 ± 25# |
61 ± 23 |
72 ± 22 |
FVC (L) |
3.5 ± 1.0** |
4.0 ± 1.2 |
3.7 ± 1.2 |
4.1 ± 0.8 |
Quadriceps strength and functional exercise capacity | ||||
Twqpot (N) |
140 ± 42 |
140 ± 47 |
129 ± 35 |
158 ± 40 |
MVC (N) |
378 ± 128 |
369 ± 119 |
353 ± 109 |
456 ± 157 |
6MWD (m) |
/ |
694 ± 89§ |
698 ± 84§ |
786 ± 111 |
Physical activity | ||||
Daily steps (n) |
4654 ± 2929#,§ |
7174 ± 4423 |
7414 ± 2810 |
|
Time > 4.8 METs (min) |
6 [2-17] # |
14 [4–40] |
11 [6–35] |
|
Hematological parameters, testosterone and systemic inflammation | ||||
Hemoglobin (g/dL) |
13.9 ± 1.5 |
13.7 ± 1.6 |
13.8 ± 1.4 |
14.8 ± 1.2 |
Blood platelets (x109/L) |
314 ± 109* |
287 ± 104 |
339 ± 87 |
250 ± 63 |
Testosterone (in men) (ng/dL) |
249 [148–281] |
354 [251–442] |
256 [209–363] |
/ |
WBC count (x109/L) |
12.6 ± 4.3**,#,§ |
8.6 ± 3.1 |
9.9 ± 2.3§ |
7.4 ± 2.2 |
Neutrophil count (x109/L) |
8.6 ± 3.0**,§ |
5.2 ± 2.4 |
7.1 ± 2.4§ |
4.7 ± 1.8 |
CRP (mg/L) | 13 [8–48]**,§ | 3 [0–5] | 9 [7-18] § | 2 [0–7] |
Data are presented as mean ± standard deviation or median [interquartile range].
Data in the stable group are data from the first assessment, except for physical activity measurements, which are the mean values over a 14-day assessment period.FEV1 = forced expiratory volume in one second; %pred = percentage of the predicted value; FVC = forced vital capacity; Twqpot = potentiated quadriceps twitch force; MVC = maximal voluntary contraction force of the quadriceps, 6MWD = six-minute walking distance, MET = metabolic equivalent, WBC = white blood cells, CRP = C-reactive protein. *p < 0.05 vs. day 14 **, p < 0.001 vs. day 14, # p < 0.05 vs. day 40, ## p < 0.001 vs. day 40, §p < 0.05 vs. stable.